Mizuho Raises Broadcom Price Target to $450 on Surging AI Chip Demand 
Samsung SDI Secures Major LFP Battery Supply Deal in the U.S. 
Air Force One Delivery Delayed to 2028 as Boeing Faces Rising Costs 
SoftBank Eyes Switch Inc as It Pushes Deeper Into AI Data Center Expansion 
CVS Health Signals Strong 2026 Profit Outlook Amid Turnaround Progress 
ANZ Faces Legal Battle as Former CEO Shayne Elliott Sues Over A$13.5 Million Bonus Dispute 
Nvidia Develops New Location-Verification Technology for AI Chips 
Trump’s Approval of AI Chip Sales to China Triggers Bipartisan National Security Concerns 
Evercore Reaffirms Alphabet’s Search Dominance as AI Competition Intensifies 
Gulf Sovereign Funds Unite in Paramount–Skydance Bid for Warner Bros Discovery 
China Adds Domestic AI Chips to Government Procurement List as U.S. Considers Easing Nvidia Export Curbs 
Azul Airlines Wins Court Approval for $2 Billion Debt Restructuring and New Capital Raise 
SoftBank Shares Slide as Oracle’s AI Spending Plans Fuel Market Jitters 
GameStop Misses Q3 Revenue Estimates as Digital Shift Pressures Growth 
Moore Threads Stock Slides After Risk Warning Despite 600% Surge Since IPO 
SpaceX Edges Toward Landmark IPO as Elon Musk Confirms Plans 
Microsoft Unveils Massive Global AI Investments, Prioritizing India’s Rapidly Growing Digital Market 
CAMBRIDGE, Mass., Feb. 09, 2017 -- Cellaria, LLC, a scientific innovator that develops revolutionary new patient-specific cancer models for challenging tumors, today announced the formation of a strategic partnership with AMS Biotechnology (AMSBIO). As part of the agreement, AMSBIO will distribute, market and sell Cellaria cell models and culture media throughout Europe. The partnership enables Cellaria to better meet growing demand for its products outside the US.
Cellaria's unique patient-specific cell models and cell culture media products expand the current offering AMSBIO has for physiologically relevant cell culture products for drug discovery and other life science applications. Late in 2016, Cellaria announced the availability of new models for High Grade Serous and Endometriod Ovarian Cancer and an ER-positive breast model.
AMSBIO is a premier provider of quality life science research reagents and services helping customers develop innovative methods, processes, products and medicines. As a leading provider of scaffolds, matrices, kits and proteins for growing and screening spheroids and organoids, AMSBIO has contributed to the acceleration of discovery programs in medical research.
Alex Sim, managing director at AMSBIO said, "The new partnership with Cellaria expands our existing portfolio by introducing patient-derived cancer models; allowing customers to conduct research and drug discovery initiatives to advance precision medicine.”
"The unique value of our patient-specific cell models makes AMSBIO an ideal partner for Cellaria," said David Deems, chief executive officer at Cellaria. "Our products will expand the AMSBIO cancer product portfolio, and their technical expertise will enable them to support Cellaria's customers throughout Europe."
About Cellaria
Cellaria creates breakthrough oncology models that reflect the unique nature and complexity of a tumor. Using these informative models, cancer researchers are better able to select promising compounds and work towards personalized approaches that would enable physicians to identify the most effective treatment for each patient's needs. Cellaria's innovative products help lead the research community to more personalized therapeutics, revolutionizing and accelerating the search for a cancer cure. For more information, visit www.cellariabio.com or to learn more about our cell models.
Contact: Tim Walsh for Cellaria Bio 617.512.1641 [email protected]
